Communiqués IDEAYA Biosciences, Inc.

Actions

IDYA

US45166A1025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:01 30/09/2026			Varia. 5j.	Varia. 1 janv.
38,42 ^USD	+1,48%		+2,56%	+11,14%

28/09	IDEAYA Biosciences, Inc. annonce la promotion de Michael White, de directeur scientifique à président chargé de la recherche et du développement, avec effet au 28 septembre 2026	CI
14/09	Transcript : IDEAYA Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM

Communiqués

28/09	IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development	PR
25/09	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
09/09	IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma	PR
31/08	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
31/08	IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer	PR
28/08	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
19/08	IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer	PR
04/08	IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update	PR
31/07	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
27/07	IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers	PR
17/07	IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs	PR
26/06	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
17/06	IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors	PR
15/06	IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers	PR
10/06	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
09/06	IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants	PR
08/06	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	PR
03/06	IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer	PR
01/06	IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO	PR
29/05	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
26/05	IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference	PR
05/05	IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update	PR
01/05	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	PR
30/04	IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program	PR
21/04	IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma	PR